{"denoms":[{"counts":[{"groupId":"BG000","value":"46"}],"units":"Participants"}],"groups":[{"description":"PHASE I: Patients receive flavopiridol IV over 4½ hours on days 1, 8, 15, and 22. Treatment repeats every 6 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of flavopiridol until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.\n\nPHASE II: Patients receive flavopiridol\\* as in phase I at the MTD determined in phase I.\n\nalvocidib: Given IV","id":"BG000","title":"Treatment (Alvocidib)"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"34","upperLimit":"84","value":"66"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"20"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"26"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"45"}]}],"title":"United States"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}],"title":"Canada"}],"paramType":"NUMBER","title":"Region of Enrollment","unitOfMeasure":"patients"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"8"}]}],"title":"0 (Fully active)"},{"categories":[{"measurements":[{"groupId":"BG000","value":"34"}]}],"title":"1 (Restricted in physically strenuous activity)"},{"categories":[{"measurements":[{"groupId":"BG000","value":"4"}]}],"title":"2 (Ambulatory capable of all selfcare)"}],"paramType":"NUMBER","title":"Eastern Cooperative Oncology Group (ECOG) Performance status","unitOfMeasure":"patients"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"15"}]}],"title":"Indolent B-cell"},{"categories":[{"measurements":[{"groupId":"BG000","value":"17"}]}],"title":"intermediate grade B-NHL"},{"categories":[{"measurements":[{"groupId":"BG000","value":"7"}]}],"title":"Mantle cell lymphoma"},{"categories":[{"measurements":[{"groupId":"BG000","value":"7"}]}],"title":"T/NK cell NHL"}],"paramType":"NUMBER","title":"Diagnosis","unitOfMeasure":"patients"}]}